Abstract
AbstractPhotodynamic therapy is witnessing a revival of its origins as a response to the rise of multi-drug resistant infections and the shortage of new classes of antibiotics. Photodynamic disinfection (PDDI) of microorganisms is making progresses in preclinical models and in clinical cases, and the perception of its role in the clinical armamentarium for the management of infectious diseases is changing. We review the positioning of PDDI from the perspective of its ability to respond to clinical needs. Emphasis is placed on the pipeline of photosensitizers that proved effective to inactivate biofilms, showed efficacy in animal models of infectious diseases or reached clinical trials. Novel opportunities resulting from the COVID-19 pandemic are briefly discussed. The molecular features of promising photosensitizers are emphasized and contrasted with those of photosensitizers used in the treatment of solid tumors. The development of photosensitizers has been accompanied by the fabrication of a variety of affordable and customizable light sources. We critically discuss the combination between photosensitizer and light source properties that may leverage PDDI and expand its applications to wider markets. The success of PDDI in the management of infectious diseases will ultimately depend on the efficacy of photosensitizers, affordability of the light sources, simplicity of the procedures, and availability of fast and efficient treatments.
Graphic abstract
Funder
fundação para a ciência e a tecnologia
Publisher
Springer Science and Business Media LLC
Subject
Physical and Theoretical Chemistry
Reference309 articles.
1. O’Neill, J. (2014). Antimicrobial resistance: Tackling a crisis for the health and wealth of nations. The Review on Antimicrobial Resistance 1–18. https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf. Accessed 16 Oct 2021
2. World-Health-Organization. (2019). WHO report on surveillance of antibiotic consumption:2016–2018 early implementation. https://www.who.int/publications/i/item/who-report-on-surveillance-of-antibiotic-consumption. Accessed 16 Oct 2021
3. Klein, E. Y., Van Boeckel, T. P., Martinez, E. M., Pant, S., Gandra, S., Levin, S. A., Goossens, H., & Laxminarayan, R. (2018). Global increase and geographic convergence in antibiotic consumption between 2000 and 2015. Proceedings of the National Academy of Sciences of the United States of America, 115(15), E3463. https://doi.org/10.1073/pnas.1717295115
4. European-Centre-for-Disease-Prevention-and-Control-(ECDC); European-Food-Safety-Authority-(EFSA); European-Medicines-Agency-(EMA). (2017). ECDC/EFSA/EMA second joint report on the integrated analysis of the consumption of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from humans and food-producing animals: Joint Interagency Antimicrobial Consumption and Resistance Analysis (JIACRA) report. EFSA Journal, 15(7), e04872. https://doi.org/10.2903/j.efsa.2017.4872
5. O'Neil, J. (2015). Antimicrobials in agriculture and the environment: Reducing unnecessary use and waste. The Review on Antimicrobial Resistance 1–41. https://amr-review.org/sites/default/files/Antimicrobials%20in%20agriculture%20and%20the%20environment%20-%20Reducing%20unnecessary%20use%20and%20waste.pdf. Accessed 16 Oct 2021
Cited by
32 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献